Newsroom | 4376 results

SAN DIEGO--(BUSINESS WIRE)--Allele Biotechnology & Pharmaceuticals, Inc. (Allele), a San Diego-based technology development and cell manufacturing company, today announced its participation in an up to $25.8 million research project with the University of California, San Diego, funded by the Advanced Research Projects Agency for Health (ARPA-H). The project’s goal is to develop a fully functional, patient-specific, 3D bioprinted liver for transplantation. This project is under ARPA-H’s Pers...

CAMBRIDGE, England & EDINBURGH, Scotland--(BUSINESS WIRE)--Axol Bioscience Ltd. (Axol), a leading provider of induced pluripotent stem cell (iPSC) technologies for drug discovery and disease research, today announced that it has secured $2.8 million (£2.1 million) in funding. The investment was led by US life sciences specialist BroadOak Capital Partners, with the company’s founding investor, the Roslin Foundation, also participating. The funding will accelerate Axol’s next phase of growth, sup...

ROCHDALE, United Kingdom--(BUSINESS WIRE)--Astoriom today announced the appointment of Will Edwards, MBA as CEO to support global scale-up of sample management operations....

BOSTON--(BUSINESS WIRE)--FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor...

SAN FRANCISCO--(BUSINESS WIRE)--Junevity Announces First Peer-reviewed Research Showing Single-Target Repression Can Reprogram Cellular Aging...

SEATTLE--(BUSINESS WIRE)--Curi Bio Launches Asia-Pacific Hub, Delivering Greater Support to its Growing APAC Business...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today provided a business update and announced strategic priorities for 2026, highlighting recent progress for its two lead programs, upcoming clinical milestones, and a strong financial position supporting execution through key value-inflection points. “We continue...

TULLINGE, Sweden & TAMPA, Fla.--(BUSINESS WIRE)--SmartCella and Catalent have entered a nonexclusive license agreement for induced pluripotent stem cells (iPSCs) for developing regenerative therapies...

CAMBRIDGE, England--(BUSINESS WIRE)--Enhanced Genomics (‘Enhanced’ or ‘the Company’), the biotechnology company pioneering 3D multi-omics to rapidly identify high-confidence, genetically validated drug targets for common diseases, today announced Katerina Leftheris, Ph.D. has joined its Board of Directors. Katerina’s appointment as a Director forms part of the Company’s ongoing strategy to expand its internal therapeutics pipeline for drug targets identified using its 3D multi-omics platform. K...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--MEDIPOST Inc., a biotechnology company developing allogeneic, umbilical cord blood-derived stem cell therapies for inflammation-driven degenerative diseases, today announced that its parent company, MEDIPOST Co., Ltd., has closed on $140 million in funding. The investment, led by Skylake Equity Partners and Crescendo Equity Partners, with participation from Korea’s leading growth equity fund, was completed at the parent-company level and will accelerate the co...